Progress of study on JAK2V617F mutation in myeloproliferative neoplasm.
- Author:
Yi-Xin CHEN
1
;
Ying LI
;
Ling-Yan ZHANG
;
Bin LIU
Author Information
1. Department of Hematology, Shandong University Affiliated Provincial Hospital, Jinan, Shandong Province, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Janus Kinase 2;
genetics;
Mutation;
Myeloproliferative Disorders;
genetics;
pathology
- From:
Journal of Experimental Hematology
2011;19(5):1329-1333
- CountryChina
- Language:Chinese
-
Abstract:
Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell diseases characterized by proliferation of one or more myeloid cell lineages in the bone marrow and increased mature and immature cells in peripheral blood. As the most important discovery in recent studies of MPN, JAk2V617F mutation is considered to closely relate with the pathogenesis of MPN. The mutated JAK2 lost self-inhibition, and then, the sustained activation leads to a series of disorders in downstream signal transduction pathways, eventually resulting in malignant cell proliferation. A variety of methods have been used in quantitative/qualitative detection of JAK2V617F mutation, and researches about JAK2V617F mutation and its clinical features have also made some progress. However, it must be noted that there are still some unsolved problems, such as the role of JAk2V617F mutation in pathogenesis of MPN needs further exploration, effective targeted therapy for JAK2 is a attractive topic, and the application of JAK2V617F mutation in disease diagnosis also requires a deep research. In this review, the latest progress from different aspects is summarized briefly, including JAK2 and JAK2V617F mutation, effects of JAK2V617F mutation on the pathogenesis, clinical correlation of JAK2V617F with MPN, and targeting therapy.
